10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2015 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Net Sales | $ 20,405 | 20,247 | 19,657 |
| Cost of products sold, excluding amortization of intangible assets | 8,747 | 9,218 | 9,193 |
| Amortization of intangible assets | 601 | 555 | 588 |
| Research and development | 1,405 | 1,345 | 1,371 |
| Selling, general and administrative | 6,785 | 6,530 | 6,372 |
| Total operating cost and expenses | 17,538 | 17,648 | 17,524 |
| Operating earnings | 2,867 | 2,599 | 2,133 |
| Interest expense | 163 | 150 | 145 |
| Interest income | (105) | (77) | (67) |
| Net loss on extinguishment of debt | 18 | ||
| Net foreign exchange (gain) loss | (93) | (24) | 46 |
| Other (income) expense, net | (281) | 14 | (32) |
| Earnings from Continuing Operations Before Taxes | 3,183 | 2,518 | 2,041 |
| Taxes on Earnings from Continuing Operations | 577 | 797 | 53 |
| Earnings from continuing operations | 2,606 | 1,721 | 1,988 |
| Earnings from Discontinued Operations, net of taxes | 65 | 563 | 588 |
| Gain on sale of Discontinued Operations, net of taxes | 1,752 | ||
| Net Earnings from Discontinued Operations, net of taxes | 1,817 | 563 | 588 |
| Net Earnings | 4,423 | 2,284 | 2,576 |
| Basic Earnings Per Common Share - | |||
| Continuing Operations (in dollars per share) | 1.73 | 1.13 | 1.27 |
| Discontinued Operations (in dollars per share) | 1.21 | 0.37 | 0.37 |
| Net Earnings (in dollars per share) | 2.94 | 1.50 | 1.64 |
| Diluted Earnings Per Common Share - | |||
| Continuing Operations (in dollars per share) | 1.72 | 1.12 | 1.26 |
| Discontinued Operations (in dollars per share) | 1.20 | 0.37 | 0.36 |
| Net Earnings (in dollars per share) | 2.92 | 1.49 | 1.62 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,496 | 1,516 | 1,558 |
| Dilutive Common Stock Options (in shares) | 10 | 11 | 16 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,506 | 1,527 | 1,574 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 1 | 1 | 1 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2015 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Net Earnings | $ 4,423 | 2,284 | 2,576 |
| Foreign currency translation (loss) adjustments | (2,013) | (2,206) | (239) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $101 in 2015, $(459) in 2014 and $393 in 2013 | 252 | (917) | 882 |
| Unrealized gains (losses) on marketable equity securities, net of taxes of $104 in 2015, $(7) in 2014 and $(10) in 2013 | 64 | (12) | (18) |
| Net (losses) gains on derivative instruments designated as cash flow hedges, net of taxes of $(9) in 2015, $24 in 2014 and $(13) in 2013 | (35) | 94 | (53) |
| Net current period comprehensive income (loss) | (1,732) | (3,041) | 572 |
| Comprehensive Income (Loss) | 2,691 | (757) | 3,148 |
| Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (4,829) | (2,924) | (718) |
| Net actuarial (losses) and prior service (cost) and credits | (1,958) | (2,229) | (1,312) |
| Cumulative unrealized gains on marketable equity securities | 65 | 1 | 13 |
| Cumulative gains on derivative instruments designated as cash flow hedges | 64 | 99 | 5 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2015 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 4,423 | 2,284 | 2,576 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 871 | 918 | 928 |
| Amortization of intangible assets | 601 | 630 | 791 |
| Share-based compensation | 292 | 246 | 262 |
| Investing and financing (gains) losses, net | (18) | 69 | 4 |
| Net loss on extinguishment of debt | 18 | ||
| Gain on sale of discontinued operations | (2,840) | ||
| Gain on sale of Mylan N.V. shares | (207) | ||
| Trade receivables | (171) | (195) | (113) |
| Inventories | (257) | (297) | (154) |
| Prepaid expenses and other assets | 57 | 30 | 131 |
| Trade accounts payable and other liabilities | (742) | (225) | (436) |
| Income taxes | 957 | 197 | (665) |
| Net Cash From Operating Activities | 2,966 | 3,675 | 3,324 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,110) | (1,077) | (1,145) |
| Acquisitions of businesses and technologies, net of cash acquired | (235) | (3,317) | (580) |
| Proceeds from business dispositions | 230 | 5 | |
| Proceeds from the sale of Mylan N.V. shares | 2,290 | ||
| Purchases of investment securities | (4,933) | (1,507) | (10,064) |
| Proceeds from sales of investment securities | 4,112 | 5,624 | 7,839 |
| Other | 52 | 70 | 21 |
| Net Cash From (Used in) Investing Activities | 406 | (202) | (3,929) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | (1,281) | 1,343 | 2,086 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 2,485 | 9 | |
| Repayments of long-term debt and debt with maturities over 3 months | (57) | (577) | (303) |
| Acquisition and contingent consideration payments related to business acquisitions | (17) | (400) | (495) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (2,237) | (2,195) | (1,605) |
| Proceeds from stock options exercised, including income tax benefit | 314 | 429 | 395 |
| Dividends paid | (1,443) | (1,342) | (882) |
| Net Cash (Used in) From Financing Activities | (2,236) | (2,742) | (6,696) |
| Effect of exchange rate changes on cash and cash equivalents | (198) | (143) | (26) |
| Net (Decrease) Increase in Cash and Cash Equivalents | 938 | 588 | (7,327) |
| Cash and Cash Equivalents, Beginning of Year | 4,063 | 3,475 | |
| Cash and Cash Equivalents, End of Year | 5,001 | 4,063 | 3,475 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 631 | 448 | 1,039 |
| Interest paid | 166 | 146 | 148 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2015 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2015 | Dec 31, 2014 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 5,001 | 4,063 |
| Investments, primarily bank time deposits and U.S. treasury bills | 1,124 | 397 |
| Trade receivables, less allowances of - 2015: $337; 2014: $310 | 3,418 | 3,586 |
| Inventories: | ||
| Finished products | 1,744 | 1,807 |
| Work in process | 316 | 278 |
| Materials | 539 | 558 |
| Total inventories | 2,599 | 2,643 |
| Other prepaid expenses and receivables | 1,908 | 1,975 |
| Current assets held for disposition | 105 | 892 |
| Total Current Assets | 14,155 | 13,556 |
| Investments | 4,041 | 229 |
| Property and Equipment, at Cost: | ||
| Land | 432 | 457 |
| Buildings | 2,769 | 2,968 |
| Equipment | 8,254 | 8,480 |
| Construction in progress | 928 | 727 |
| Property and equipment, at cost | 12,383 | 12,632 |
| Less: accumulated depreciation and amortization | 6,653 | 6,697 |
| Net property and equipment | 5,730 | 5,935 |
| Intangible assets, net of amortization | 5,562 | 6,198 |
| Goodwill | 9,638 | 10,067 |
| Deferred income taxes and other assets | 2,119 | 3,288 |
| Non-current assets held for disposition | 2 | 1,934 |
| Total Assets | 41,247 | 41,207 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 3,127 | 4,382 |
| Trade accounts payable | 1,081 | 1,064 |
| Salaries, wages and commissions | 746 | 776 |
| Other accrued liabilities | 3,043 | 2,878 |
| Dividends payable | 383 | 362 |
| Income taxes payable | 430 | 270 |
| Current portion of long-term debt | 3 | 55 |
| Current liabilities held for disposition | 373 | 680 |
| Total Current Liabilities | 9,186 | 10,467 |
| Long-term debt | 5,871 | 3,393 |
| Post-employment Obligations, deferred income taxes and other long - term Liabilities | 4,864 | 5,600 |
| Non-current liabilities held for disposition | 108 | |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2015: 1,702,017,390; 2014: 1,694,929,949 | 12,734 | 12,383 |
| Common shares held in treasury, at cost - Shares: 2015: 229,352,338; 2014: 186,894,515 | (10,622) | (8,678) |
| Earnings employed in the business | 25,757 | 22,874 |
| Accumulated other comprehensive income (loss) | (6,658) | (5,053) |
| Total Abbott Shareholders' Investment | 21,211 | 21,526 |
| Noncontrolling Interests in Subsidiaries | 115 | 113 |
| Total Shareholders' Investment | 21,326 | 21,639 |
| Total Liabilities and Shareholders' Investment | 41,247 | 41,207 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |